Methoxamine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search

<templatestyles src="Module:Hatnote/styles.css"></templatestyles>

Lua error in Module:Infobox at line 314: malformed pattern (missing ']').

Methoxamine Hydrochloride is an α1-adrenergic receptor agonist,[1] SNRI, MDMA agonist somewhat similar in structure to butaxamine and 2,5-DMA. It was first theorised and synthesised by British pharmacologist Oliver Ansell in 2015 and then patented on January 4, 2016. The compound has been accepted for preliminary clinical trials.[2] Methoxamine is a theoretical novel fast-acting antidepressant with mood lifting qualities that may alleviate the symptoms of clinical depression as an ultra-fast onset agent, in comparison to SSRIs, MAOIs and even tricyclic and tetracyclic antidepressants. Which all have a significantly long period of time for the optimum peak blood concentration is attained, commonly leading to patients to discontinue their treatment and can also induce suicidal ideation.

This is not the case with Methoxamine, as it readily crosses the blood brain barrier and stimulates the release of serotonin, inhibits the re-uptake of norepinephrine. Mood lift is also expected to be enhanced by the M1 metabolite, which weakly binds to μ-opioid receptors (approximate potency is comparable of that of dextropropoxyphene.but at proper prescribed doses and time frames there is a very low risk of this causing any dependency or tolerance to the effect)

Methoxamine in Clinical Trials

File:Methoxamine in it's current manufactured form in a solution in both a syringe and vial..jpg
Methoxamine HCl shown here in its pre-market manufactured state for early phase clinical research.

For example, a standard sublingual dose of 15 mg would be equipotent between 5–25 mg of dextropropoxyphene depending on the metabolism of the individual. Although this in no way implies that methoxamine or its metabolites resemble dextropropoxyphene, it is simply a weak opioid from which an easy comparison can be drawn.

The drug occasionally induces slight vasoconstriction of skin and splanchnic blood vessels, thereby increasing peripheral vascular resistance and raising mean arterial blood pressure. Because of its hypertensive effects, it may evoke a compensatory reflex bradycardia via the baroreceptors.



See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


<templatestyles src="Asbox/styles.css"></templatestyles>

<templatestyles src="Asbox/styles.css"></templatestyles>

  1. Lua error in package.lua at line 80: module 'strict' not found.
  2. US Patent 2359707 - DIMETHOXYPHENYL beta-HYDROXY ISOPROPYLAMINE